These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

963 related articles for article (PubMed ID: 34016740)

  • 1. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
    Yuan M; Huang D; Lee CD; Wu NC; Jackson AM; Zhu X; Liu H; Peng L; van Gils MJ; Sanders RW; Burton DR; Reincke SM; Prüss H; Kreye J; Nemazee D; Ward AB; Wilson IA
    Science; 2021 Aug; 373(6556):818-823. PubMed ID: 34016740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
    Yuan M; Huang D; Lee CD; Wu NC; Jackson AM; Zhu X; Liu H; Peng L; van Gils MJ; Sanders RW; Burton DR; Reincke SM; Prüss H; Kreye J; Nemazee D; Ward AB; Wilson IA
    bioRxiv; 2021 Feb; ():. PubMed ID: 33619487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
    Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
    Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain.
    Wu J; Nie J; Zhang L; Song H; An Y; Liang Z; Yang J; Ding R; Liu S; Li Q; Li T; Cui Z; Zhang M; He P; Wang Y; Qu X; Hu Z; Wang Q; Huang W
    Signal Transduct Target Ther; 2022 Jan; 7(1):18. PubMed ID: 35046385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of spike mutations on SARS-CoV-2 neutralization.
    Rees-Spear C; Muir L; Griffith SA; Heaney J; Aldon Y; Snitselaar JL; Thomas P; Graham C; Seow J; Lee N; Rosa A; Roustan C; Houlihan CF; Sanders RW; Gupta RK; Cherepanov P; Stauss HJ; Nastouli E; ; Doores KJ; van Gils MJ; McCoy LE
    Cell Rep; 2021 Mar; 34(12):108890. PubMed ID: 33713594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies.
    Reincke SM; Yuan M; Kornau HC; Corman VM; van Hoof S; Sánchez-Sendin E; Ramberger M; Yu W; Hua Y; Tien H; Schmidt ML; Schwarz T; Jeworowski LM; Brandl SE; Rasmussen HF; Homeyer MA; Stöffler L; Barner M; Kunkel D; Huo S; Horler J; von Wardenburg N; Kroidl I; Eser TM; Wieser A; Geldmacher C; Hoelscher M; Gänzer H; Weiss G; Schmitz D; Drosten C; Prüss H; Wilson IA; Kreye J
    Science; 2022 Feb; 375(6582):782-787. PubMed ID: 35076281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad Neutralization Capacity of an Engineered Thermostable Three-Helix Angiotensin-Converting Enzyme 2 Polypeptide Targeting the Receptor-Binding Domain of SARS-CoV-2.
    Cavazzini D; Levati E; Germani S; Ta BL; Monica L; Bolchi A; Donofrio G; Garrapa V; Ottonello S; Montanini B
    Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 correlates of protection from infection against variants of concern.
    Sun K; Bhiman JN; Tempia S; Kleynhans J; Madzorera VS; Mkhize Q; Kaldine H; McMorrow ML; Wolter N; Moyes J; Carrim M; Martinson NA; Kahn K; Lebina L; du Toit JD; Mkhencele T; von Gottberg A; Viboud C; Moore PL; Cohen C;
    Nat Med; 2024 Oct; 30(10):2805-2812. PubMed ID: 39060660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
    Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
    Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.
    Wang M; Zhang L; Li Q; Wang B; Liang Z; Sun Y; Nie J; Wu J; Su X; Qu X; Li Y; Wang Y; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):18-29. PubMed ID: 34818119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
    Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
    Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
    Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
    Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
    Liu H; Yuan M; Huang D; Bangaru S; Zhao F; Lee CD; Peng L; Barman S; Zhu X; Nemazee D; Burton DR; van Gils MJ; Sanders RW; Kornau HC; Reincke SM; Prüss H; Kreye J; Wu NC; Ward AB; Wilson IA
    Cell Host Microbe; 2021 May; 29(5):806-818.e6. PubMed ID: 33894127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
    Greaney AJ; Starr TN; Barnes CO; Weisblum Y; Schmidt F; Caskey M; Gaebler C; Cho A; Agudelo M; Finkin S; Wang Z; Poston D; Muecksch F; Hatziioannou T; Bieniasz PD; Robbiani DF; Nussenzweig MC; Bjorkman PJ; Bloom JD
    Nat Commun; 2021 Jul; 12(1):4196. PubMed ID: 34234131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A broad and potent neutralization epitope in SARS-related coronaviruses.
    Yuan M; Zhu X; He WT; Zhou P; Kaku CI; Capozzola T; Zhu CY; Yu X; Liu H; Yu W; Hua Y; Tien H; Peng L; Song G; Cottrell CA; Schief WR; Nemazee D; Walker LM; Andrabi R; Burton DR; Wilson IA
    Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2205784119. PubMed ID: 35767670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.
    Cele S; Jackson L; Khoury DS; Khan K; Moyo-Gwete T; Tegally H; San JE; Cromer D; Scheepers C; Amoako DG; Karim F; Bernstein M; Lustig G; Archary D; Smith M; Ganga Y; Jule Z; Reedoy K; Hwa SH; Giandhari J; Blackburn JM; Gosnell BI; Abdool Karim SS; Hanekom W; ; ; von Gottberg A; Bhiman JN; Lessells RJ; Moosa MS; Davenport MP; de Oliveira T; Moore PL; Sigal A
    Nature; 2022 Feb; 602(7898):654-656. PubMed ID: 35016196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.